Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-10T05:07:59.353Z Has data issue: false hasContentIssue false
  • English
  • Français

Antimicrobial stewardship in patients with confirmed coronavirus disease 2019 (COVID-19)

Part of: SARS-CoV-2/COVID-19

Published online by Cambridge University Press:  02 August 2021

Sarah E. Moore Open the ORCID record for Sarah E. Moore [Opens in a new window] ,
Ashley M. Wilde ,
Brian C. Bohn ,
Matthew Song  and
Paul Schulz
Sarah E. Moore*
Affiliation:
Norton Infectious Diseases Institute, Norton Healthcare, Louisville, Kentucky
Ashley M. Wilde
Affiliation:
Norton Infectious Diseases Institute, Norton Healthcare, Louisville, Kentucky
Brian C. Bohn
Affiliation:
Norton Infectious Diseases Institute, Norton Healthcare, Louisville, Kentucky
Matthew Song
Affiliation:
Norton Infectious Diseases Institute, Norton Healthcare, Louisville, Kentucky
Paul Schulz
Affiliation:
Norton Infectious Diseases Institute, Norton Healthcare, Louisville, Kentucky
*
Author for correspondence: Sarah E. Moore, E-mail: sarah.moore@nortonhealthcare.org
Get access Rights & Permissions [Opens in a new window]

Abstract

Hospitalized coronavirus disease 2019 (COVID-19) patients receiving antibiotics (n = 173) were retrospectively assigned to the early or late discontinuation groups. The length of therapy was shorter in the early discontinuation group (3 vs 7 days; P < .0001). Mortality rates (14.3% vs 20.7%; P = .316) and length of stay (7 vs 9 days; P = .063) were similar.

Type
Concise Communication
Information
Infection Control & Hospital Epidemiology , Volume 43 , Issue 11 , November 2022 , pp. 1698 - 1700
Check for updates
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Rawson, TM, Moore, LSP, Castro-Sanchez, E, et al. COVID-19 and the potential long-term impact on antimicrobial resistance. J Antimicrob Chemother 2020;75:1681–1684.CrossRefGoogle ScholarPubMed
Spernovsilis, NA, Kofteridis, DP. COVID-19 and antimicrobial stewardship: what is the interplay? Infect Control Hosp Epidemiol 2021;42:378–379.CrossRefGoogle Scholar
Rawson, TM, Moore, LSP, Zhu, N, et al. Bacterial and Fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis 2020;71:2459–2468.Google ScholarPubMed
Vaughn, VM, Gandhi, T, Petty, AP, et al. Empiric antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with COVID-19: a multi-hospital cohort study, Clin Infect Dis 2020. doi: 10.1093/cid/ciaa1239.Google Scholar
Heesom, L, Rehnberg, L, Nasim-Mohi, M, et al. Procalcitonin as an antibiotic stewardship tool in COVID-19 patients in the intensive care unit. J Glob Antimicrob Resist 2020;22:782–784.Google ScholarPubMed
Beović, B, Doušak, M, Ferreira-Coimbra, J, et al. Antibiotic use in patients with COVID-19: a ‘snapshot’ Infectious Diseases International Research Initiative (ID-IRI) survey. J Antimicrob Chemother 2020;75:3386–3390.CrossRefGoogle ScholarPubMed
About variants of the virus that cause COVID-19. Centers for Disease Control and Prevention website. https://www.cdc.gov/coronavirus/2019-ncov/variants/variant.html. Updated June 28, 2021. Accessed June 30, 2021.Google Scholar